Interactions between radiation and hormonal therapy in breast cancer: Simultaneous or sequential treatment;Sugár- és hormonterápia kölcsönös hatása emlorákban: Szimultán vagy szekvenciális kezelés

Orvosi Hetilap

Volumn 147, Issue 3, 2006, Pages 121-125

  Fodor, János ^a,b  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b NONE   (Hungary)

Author keywords

Breast cancer; Hormonal treatment; Interaction; Irradiation

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; RADIOSENSITIZING AGENT; TRIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST FIBROSIS; CANCER CELL CULTURE; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE ARREST; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG RESPONSE; EVIDENCE BASED MEDICINE; HUMAN; LUNG FIBROSIS; MASTECTOMY; MEDLINE; MULTIMODALITY CANCER THERAPY; NONHUMAN; OUTCOME ASSESSMENT; RADIATION PROTECTION; RADIATION RESPONSE; RADIOSENSITIZATION; RECURRENT CANCER; REVIEW; THERAPY EFFECT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANIMAL; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; DISEASE MODEL; DRUG ADMINISTRATION; FEMALE; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; NITRILES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TRIAZOLES;

EID: 33645924049     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Ahn, P. H., Vu, H. T, Lannin, D. és mtsai: Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J. Clin. Oncol., 2005, 23, 17-23.
2. Azria, D., Gourgou, S., Sozzi, W. J. és mtsai: Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. Br. J. Cancer, 2004, 91, 1251-1260.
3. Azria, D., Larbouret, C., Cunat, S. és mtsai: Letrozole (Femara) sensitises breast cancer cells to gamma irradiation. Int. J. Radiat. Oncol. Biol. Phys., 2003, 57, 255-256.
4. Baum M., Budzar A. U., Cuzick J. és mtsai: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 2002, 359, 2131-2139.
5. Bentzen, S. M., Skocylas, J. Z., Overgaard, M. és mtsai: Radiotherapy-related lung fibrosis enhanced by tamoxifen. J. Natl. Cancer Inst., 1996, 88, 918-922.
6. Border, W. A., Noble, N. A.: Transforming growth factor beta in tissue fibrosis. N. Eng. J. Med., 1994, 331, 1286-1292.
7. Böhning, K., Busch, M., Rave-Frank, M. és mtsa: Effect of tamoxifen and estrogen treatment on the radiosensitivity of MCF-7 breast cancer cells. Onkologie, 1996, 19, 163-169.
8. Dalberg, K., Johansson, H., Johansson, U. és mtsa: A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery. Cancer, 1998, 82, 2090-2092.
9. Early Breast Cancer Trialist' Collaborative Group: Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet, 2000, 355, 1757-1770.
10. Eckhardt S.: Az emlorák endokrin kezelésének kutatási távlatai. Magy. Onkol., 2003, 47, 133-140.
11. Fodor, J., Major T., Polgár C. és mtsai: The impact of radiotherapy on the incidence and time of occurrence of local recurrence in early-stage breast cancer after breast conserving therapy. Neoplasma, 2000, 47, 181-186.
12. Fodor J., Polgár Cs., Németh Gy.: Az operábilis emlorák bizonyítékokon alapuló sugárkezelése: az 1990-es évek eredményeinek elemzése. Orv. Hetil., 2000, 141, 1551-1555.
13. Fowble, B., Fein, D. A., Hanlon, A. L., é mtsai: The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in eostrogen receptor-positive early-stage breast cancer. Int. J. Radiat. Oncol. Biol. Phys., 1996, 35, 669-677.
14. Fyles, A. W., McCready, D. R., Manchul, L. A. és misai: Tamoxifen with or without irradiation in women 50 years of age or older with early breast cancer. N. Engl. J. Med., 2004, 351, 963-970.
15. Harris, E. E., Christensen, V. J., Hwang, W. T. és mtsai: Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J. Clin. Oncol., 2005, 23, 11-16.
16. Inano, H., Onoda, M., Suzuki, K. és mtsai: Prevention of radiation induced mammary tumours in rats by combined use of WR-2721 and tamoxifen. Int. J. Radiat. Biol., 2002, 76, 1113-1120.
17. Kahan, Z.: Hormone therapy in breast cancer. Ther. Hung., 1992, 40, 154-162.
18. Kantorowitz D. A., Thompson, H. J., Furmanski, P.: Effect of conjoint administration of tamoxifen and high-dose irradiation on the development of mammary carcinomas. Int. J. Radiat. Oncol. Biol. Phys., 1993, 26, 89-94.
19. Koc, M., Polat, P., Suma, S.: Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients. Radiother. Oncol., 2002, 64, 171-175.
20. Nagykálnai T.: Szelektív ösztrogénreceptor-modulátorok (SERM-ek) a gyakorlatban. Magy. Onkol., 2002, 46, 165-175.
21. Newton, C. J., Schlatterer, K., Stalla, G. K. és mtsai: Pharmacological enhancement of radiosurgery response: studies on an in vitro model system. J. Radiosurg., 1998, 1, 51-56.
22. Osborne, C. K., Boldt, D. H., Clark, G. M. és mtsai: Effect of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res., 1983, 43, 3583-3585.
23. Pierce, L. J., Hutchins, L. F., Green, S. R. és mtsai: Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J. Clin. Oncol., 2005, 23, 24-29.
24. Polgár C, Fodor J, Németh G.: A korai emlorák sugárkezelése: Több mint lokoregionális daganatkontroll. Magy. Onkol., 2001, 45, 361-371.
25. Sarkaria, J. N., Miller, E. M., Parker, C. J. és mtsai: 4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiated in vitro. Breast Cancer Res. Treat., 1994, 30, 159-165.
26. Sinclair, W. K.: Cyclic x-ray responses in mammalian cells in vitro. Radiat. Res., 1968, 33, 620-643.
27. Thomas, E., Hortobagyi, G. N.: New paradigms in adjuvant systemic therapy of breast cancer. Endocrine Related Cancer, 2003, 10, 75-89.
28. Villalobos,M.,Aranda, M., Nunez, M. I. és mtsai: Interaction between ionizing radiation, estrogens and antiestrogens in the modification of tumor microenvironment in estrogen dependent multicellular spheroids. Acta Oncol., 1995, 34, 413-417.
29. Wazer, D. E., Morr, J., Erban, J. K. és mtsai: The effects of postirradiation treatment with tamoxifen on local control and cosmetic outcome in the conservatively treated breast. Cancer, 1997, 80, 732-740.
30. Wazer, D. E., Tercilla, O. F., Lin, P. S. és mtsa: Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17b-estradiol and tamoxifen. Br. J. Radiol., 1989, 62, 1079-1083.
31. Wennberg, B., Gagliardi, G., Sundbom, L. és mtsai: Early response of lung in breast cancer irradiation: radiologic density changes measured by CT and symptomatic radiation pneumonitis. Int. J. Radiat. Oncol. Biol. Phys., 2002, 52, 1196-1206.